Drugs / ID-LV305
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03450122 | Sep 2018 → Dec 2022 | myxoid liposarcoma, synovial sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02122861 | May 2014 → Nov 2018 | non-small cell lung carcinoma | Immune Design | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ID-LV305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02122861 ↗ |
| Route | Other | “dendritic cell-targeting lentiviral vector ID-LV305 intradermally (ID)” NCT03450122 ↗ |